Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acute Bacterial Infections Clear all
Completed Not applicable Interventional Results available

Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort

NCT02910037
View directory record Official record
Conditions
Encephalitis, Meningitis
Interventions
mNGS for pathogen detection
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Minute to 110 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Davis, California • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Jul 23, 2026, 5:30 AM EDT
Completed No phase listed Observational

Blood Volume Assessment in COVID-19 and Bacterial Sepsis

NCT04517695
View directory record Official record
Conditions
Covid19, Acute Respiratory Distress Syndrome, Bacterial Sepsis, Bacterial Infections
Interventions
BVA-100, Transpulmonary Thermodilution (TPTD), Sublingual Microcirculation
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 95 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Bethesda, Maryland • New York, New York • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jul 23, 2026, 5:30 AM EDT
Completed Phase 4 Interventional

Cefiderocol Pharmacokinetics in Adult Patients With Cystic Fibrosis

NCT05314764
View directory record Official record
Conditions
Cystic Fibrosis, Pneumonia, Bacterial
Interventions
Cefiderocol
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Hartford, Connecticut • Indianapolis, Indiana • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Jul 23, 2026, 5:30 AM EDT
Completed Phase 4 Interventional

Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox

NCT00668304
View directory record Official record
Conditions
Maxillary Sinusitis
Interventions
Avelox (Moxifloxacin, BAY12-8039)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
29
States / cities
Birmingham, Alabama • Hoover, Alabama • Jonesboro, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Jul 23, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection

NCT03747497
View directory record Official record
Conditions
Skin Diseases, Bacterial, Gram-Positive Bacterial Infections
Interventions
contezolid acefosamil, linezolid 600 mg
Drug
Lead sponsor
MicuRx
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Chula Vista, California • La Mesa, California • Long Beach, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Jul 23, 2026, 5:30 AM EDT
Terminated Phase 3 Interventional

DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)

NCT00302341
View directory record Official record
Conditions
Pneumonia, Interstitial Plasma Cell, Pneumocystis Carinii Pneumonia, Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pafuramidine maleate (DB289), Trimethoprim-Sulfamethoxazole (TMP-SMX)
Drug
Lead sponsor
Immtech Pharmaceuticals, Inc
Industry
Eligibility
13 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
7
States / cities
San Francisco, California • Chicago, Illinois • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Jul 23, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

NCT01119105
View directory record Official record
Conditions
Bacterial Infections, Infection
Interventions
BC-3781, Vancomycin
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
9
States / cities
Chula Vista, California • La Mesa, California • Oceanside, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Jul 23, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis

NCT03253094
View directory record Official record
Conditions
Candida Vulvovaginitis
Interventions
Fluconazole, SCY-078
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Jul 23, 2026, 5:30 AM EDT
Completed No phase listed Observational

Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization

NCT02888197
View directory record Official record
Conditions
Candidiasis, Vulvovaginal, Yeast Infection, Mycoses, Moniliasis, Vulvovaginal, Vaginitis, Monilial
Interventions
Not listed
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Jul 23, 2026, 5:30 AM EDT
Completed Not applicable Interventional

Guidelines for Acute Sinusitis

NCT00132275
View directory record Official record
Conditions
Sinusitis
Interventions
Amoxicillin potassium clavulanate
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
1 Year to 10 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2008 · Synced Jul 23, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults

NCT02168946
View directory record Official record
Conditions
Urinary Tract Infection Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia, Abdominal Infection
Interventions
Vabomere, Best Available Therapy
Drug
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
20
States / cities
Hartford, Connecticut • Tampa, Florida • Augusta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2019 · Synced Jul 23, 2026, 5:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV

NCT00001119
View directory record Official record
Conditions
HIV Infections
Interventions
Tetanus Toxoid Vaccine, Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Abacavir sulfate, Amprenavir, Efavirenz, Hepatitis B Vaccine (Recombinant), Lamivudine, Zidovudine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
288 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
11
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Jul 23, 2026, 5:30 AM EDT
Completed Not applicable Interventional

A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

NCT00002068
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Fluconazole, Amphotericin B
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Francisco, California • Wilmington, Delaware • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 5:30 AM EDT
Withdrawn Phase 1 Interventional

Safety, Tolerability, and Pharmacokinetics of Sulopenem in Adolescents

NCT04700787
View directory record Official record
Conditions
Urinary Tract Infections, Pyelonephritis Acute, Intraabdominal Infections
Interventions
Sulopenem
Drug
Lead sponsor
Iterum Therapeutics, International Limited
Industry
Eligibility
12 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 12, 2022 · Synced Jul 23, 2026, 5:30 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections

NCT00948142
View directory record Official record
Conditions
Skin Diseases, Bacterial
Interventions
CEM-102, Linezolid
Drug
Lead sponsor
Arrevus Inc.
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Chula Vista, California • La Mesa, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Jul 23, 2026, 5:30 AM EDT
Terminated Phase 4 Interventional Results available

Hospital Avoidance Strategies for ABSSSI

NCT03372941
View directory record Official record
Conditions
Skin Infection
Interventions
Dalbavancin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Jul 23, 2026, 5:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Establish MeMed BV™ Performance for Differentiating Bacterial From Viral Infection in Suspected Acute Infection Patients (APOLLO STUDY)

NCT04690569
View directory record Official record
Conditions
Acute Infection
Interventions
MeMed BV
Diagnostic Test
Lead sponsor
MeMed Diagnostics Ltd.
Industry
Eligibility
90 Days and older
Enrollment
1,384 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
9
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 23, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

BAY12-8039: 5 Days for Sinusitis vs Placebo

NCT00492024
View directory record Official record
Conditions
Sinusitis
Interventions
Moxifloxacin (Avelox, BAY12-8039), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
51
States / cities
Birmingham, Alabama • Northport, Alabama • Jonesboro, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Jul 23, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT02127970
View directory record Official record
Conditions
Abscess, Wound Infection, Surgical Site Infection, Cellulitis
Interventions
Dalbavancin, Dalbavancin-matching Placebo
Drug
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Industry
Eligibility
18 Years to 85 Years
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
25
States / cities
Montgomery, Alabama • Anaheim, California • Long Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Jul 23, 2026, 5:30 AM EDT
Recruiting Phase 2 Interventional

Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence

NCT07521137
View directory record Official record
Conditions
Candidiasis, Vulvovaginal
Interventions
OCF001 Intravaginal Gel, Placebo Gel
Drug
Lead sponsor
Sano Chemicals Inc
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 23, 2026, 5:30 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

NCT02961764
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
Usual Care, Dalbavancin
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Phoenix, Arizona • Sylmar, California • Hartford, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Jul 23, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia

NCT01307579
View directory record Official record
Conditions
Acute Myeloid Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With Minimal Differentiation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia, Childhood Acute Monoblastic Leukemia, Childhood Acute Monocytic Leukemia, Childhood Acute Myeloid Leukemia in Remission, Childhood Acute Myeloid Leukemia With Maturation, Childhood Acute Myeloid Leukemia With Minimal Differentiation, Childhood Acute Myeloid Leukemia Without Maturation, Childhood Acute Myelomonocytic Leukemia, Fungal Infection, Myeloid Neoplasm, Neutropenia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Myeloid Neoplasm
Interventions
Caspofungin Acetate, Fluconazole, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Months to 30 Years
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
166
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 125 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Jul 23, 2026, 5:30 AM EDT
Completed Not applicable Interventional

Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

NCT00000708
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Flucytosine, Fluconazole, Amphotericin B
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Miami, Florida • New Orleans, Louisiana • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2011 · Synced Jul 23, 2026, 5:30 AM EDT
Recruiting Phase 2 Interventional

SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)

NCT07021794
View directory record Official record
Conditions
Post-COVID / Long-COVID
Interventions
Placebo, Sipavibart
Drug · Biological
Lead sponsor
Nancy Klimas
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Jul 23, 2026, 5:30 AM EDT